- Abiomed (NASDAQ:ABMD) Q3 results: Revenues: $200.6M (+30.3%).
- Impella pump sales: $193.3M (+31%).
- Net Income: $44.9M (+235.1%); EPS: $0.97 (+234.5%).
- FY 2019 Guidance: Revenue: ~$780M from a range of $765M to $770M.
- The consensus EPS and Revenue estimate were $0.94 and $196.47M, respectively.
- Shares are up 2% premarket.
- Previously: Abiomed beats by $0.03, beats on revenue (Jan. 31)